Kura Oncology, INC. (KURA) — 10-Q Filings

10-Q Filings (6)

• Kura Oncology's Q3 Loss Widens Amid Soaring R&D, Despite Revenue Boost — Nov 4, 2025 Risk: high
  Kura Oncology, Inc. reported a significant increase in collaboration revenue, reaching $50.146 million for the nine months ended September 30, 2025, compared to
• Kura Oncology's Q2 Loss Widens Amid Rising R&D Costs — Aug 7, 2025 Risk: high
  Kura Oncology, Inc. reported a net loss of $43.9 million for the three months ended June 30, 2025, an increase from a net loss of $38.7 million in the prior-yea
• Kura Oncology Files Q1 2025 10-Q — May 1, 2025 Risk: medium
  Kura Oncology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations, including de
• Kura Oncology Q3 2024: Financials and Investments — Nov 7, 2024 Risk: medium
  Kura Oncology, Inc. reported its third quarter 2024 results, ending September 30, 2024. The company's financial statements show significant cash and cash equiva
• Kura Oncology Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Kura Oncology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Key financial figures in
• Kura Oncology, Inc. Files 10-Q for Period Ending March 31, 2024 — May 2, 2024 Risk: low
  Kura Oncology, Inc. (KURA) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Kura Oncology, Inc. filed a 10-Q report for the period ending March 31,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX